Hematologic cancer drug prices not cost-effective, may compromise patient adherence

the Oncology Nurse Advisor take:

Researchers at The University of Texas MD Anderson Cancer Center conducted a study on current hematologic cancer drug prices and its potential impact on cancer care.

They found that the majority of existing drugs for hematologic cancers are priced too high to be considered cost-effective in the United States.

Substantial improvements in survival and quality of life have been achieved in recent years. However, rising drug prices may force many patients to choose between continuing their drug treatment plans or saving money for their families’ future.

Cost-effectiveness is commonly interpreted in terms of the cost needed to gain an additional quality year of life. A widely accepted threshold value is $50,000; costs below this amount are considered cost-effective.

The researchers re-analyzed results of 20 studies on drugs for various hematologic cancers, using current drug prices in US dollars. They found that costs exceed the $50,000 threshold in 63% of the studies.

The increase in drug prices is not due to new and improved versions of the drugs; it is simply due to drug companies charging higher prices for their drugs.

The researchers conclude that following the European practice of regulating the costs of new treatments will make health care more affordable and valuable for both patients and providers in the United States.